secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001824293-24-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports FY2023 net loss of $13.0M; cash runway extended into Q3 2024 after $5.5M offering
--------------------------------------------------------------------------------

- Net loss of $13.0M for FY2023; R&D expense $3.2M (up from $0.2M) and G&A $8.2M (up from $2.0M).
- Cash and equivalents $1.8M as of Dec 31, 2023; subsequent Feb 2024 public offering raised $5.5M.
- Phase 2a biomarker study for lead IPF drug GRI-0621 ongoing; interim data H1 2024, topline H2 2024.
- GRI-0803 for SLE completing IND-enabling studies; IND filing on track for H1 2024.
- Received notice of allowance for Canadian patent covering proprietary NKT cell modulators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000037/0001824293-24-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000037/val-20240401.htm
  HTML page:      https://secwatch.observer/filing/0001824293-24-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer